University of Kentucky Markey Cancer Center | Strategic Alliance Partners

September 04, 2018

Anthracyclines widely used for a variety of malignancies cause cardiotoxic effects that manifest as cardiomyopathy. Maya E. Guglin, MD, PhD, discusses supportive therapy for these patients.

October 28, 2016

The natural products produced by microbes found in the environment have led to major therapeutic breakthroughs for a variety of conditions ranging from infectious disease to cancer.

September 09, 2016

John A. D'Orazio, MD, PhD, associate professor, Department of Pediatrics, College of Medicine, University of Kentucky Markey Cancer Center, discusses ongoing research exploring ultraviolet radiation signature mutations in patients with melanoma.

August 30, 2016

Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.

June 30, 2016

The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.

November 27, 2015

The efforts of the Kentucky LEADS Collaborative offer a unique opportunity to change the face of lung cancer in Kentucky by harnessing new lung cancer care and control strategies.

October 20, 2015

Kentucky's only NCI cancer center, Markey focuses on bringing the latest therapies to its home state.

July 14, 2014

Cardiac events associated with trastuzumab are mostly reversible and outweighed by significant extensions in OS and PFS for patients with HER2-positive breast cancer, according to analyses from several clinical trials exploring the drug.